Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,603 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Axonal loss influences the response to rituximab treatment in neuropathy associated with IgM monoclonal gammopathy with anti-myelin-associated glycoprotein antibody.
Kawagashira Y, Koike H, Ohyama K, Hashimoto R, Iijima M, Adachi H, Katsuno M, Chapman M, Lunn M, Sobue G. Kawagashira Y, et al. Among authors: chapman m. J Neurol Sci. 2015 Jan 15;348(1-2):67-73. doi: 10.1016/j.jns.2014.11.006. Epub 2014 Nov 13. J Neurol Sci. 2015. PMID: 25467141 Clinical Trial.
Do cerebrospinal fluid transfer methods affect measured amyloid β42, total tau, and phosphorylated tau in clinical practice?
Paterson RW, Toombs J, Chapman MD, Nicholas JM, Heslegrave AJ, Slattery CF, Foulkes AJ, Clark CN, Lane CA, Weston PS, Lunn MP, Fox NC, Zetterberg H, Schott JM. Paterson RW, et al. Among authors: chapman md. Alzheimers Dement (Amst). 2015 Jul 2;1(3):380-4. doi: 10.1016/j.dadm.2015.06.003. eCollection 2015 Sep. Alzheimers Dement (Amst). 2015. PMID: 27239518 Free PMC article.
Cerebrospinal fluid in the differential diagnosis of Alzheimer's disease: clinical utility of an extended panel of biomarkers in a specialist cognitive clinic.
Paterson RW, Slattery CF, Poole T, Nicholas JM, Magdalinou NK, Toombs J, Chapman MD, Lunn MP, Heslegrave AJ, Foiani MS, Weston PSJ, Keshavan A, Rohrer JD, Rossor MN, Warren JD, Mummery CJ, Blennow K, Fox NC, Zetterberg H, Schott JM. Paterson RW, et al. Among authors: chapman md. Alzheimers Res Ther. 2018 Mar 20;10(1):32. doi: 10.1186/s13195-018-0361-3. Alzheimers Res Ther. 2018. PMID: 29558979 Free PMC article.
Laboratory biomarkers associated with COVID-19 severity and management.
Keddie S, Ziff O, Chou MKL, Taylor RL, Heslegrave A, Garr E, Lakdawala N, Church A, Ludwig D, Manson J, Scully M, Nastouli E, Chapman MD, Hart M, Lunn MP. Keddie S, et al. Among authors: chapman md. Clin Immunol. 2020 Dec;221:108614. doi: 10.1016/j.clim.2020.108614. Epub 2020 Oct 22. Clin Immunol. 2020. PMID: 33153974 Free PMC article.
CSF biomarkers for dementia.
Keshavan A, O'Shea F, Chapman MD, Hart MS, Lunn MP, Paterson RW, Rohrer JD, Mummery CJ, Fox NC, Zetterberg H, Schott JM. Keshavan A, et al. Among authors: chapman md. Pract Neurol. 2022 Aug;22(4):285-294. doi: 10.1136/practneurol-2021-003310. Epub 2022 Mar 17. Pract Neurol. 2022. PMID: 35301255
Seed amplification and neurodegeneration marker trajectories in individuals at risk of prion disease.
Mok TH, Nihat A, Majbour N, Sequeira D, Holm-Mercer L, Coysh T, Darwent L, Batchelor M, Groveman BR, Orr CD, Hughson AG, Heslegrave A, Laban R, Veleva E, Paterson RW, Keshavan A, Schott JM, Swift IJ, Heller C, Rohrer JD, Gerhard A, Butler C, Rowe JB, Masellis M, Chapman M, Lunn MP, Bieschke J, Jackson GS, Zetterberg H, Caughey B, Rudge P, Collinge J, Mead S. Mok TH, et al. Among authors: chapman m. Brain. 2023 Jun 1;146(6):2570-2583. doi: 10.1093/brain/awad101. Brain. 2023. PMID: 36975162 Free PMC article.
2,603 results